Primary immune thrombocytopenia (ITP) treated with romiplostim in routine clinical practice: retrospective study from the United Kingdom ITP Registry. (7th March 2019)

• Record Type: Journal Article
• Authors: Doobaree, Indraraj Umesh; Newland, Adrian; McDonald, Vickie; Nandigam, Raghava; Mensah, Lesley; Leroy, Sandrine; Seesaghur, Anouchka; Patel, Hitan; Wetten, Sally; Provan, Drew
• Is Part Of: European journal of haematology. Volume 102:Number 5(2019)
• Page Start: 416
• Page End: 423
• Publication Date: 2019-03-07
• Subjects: bleeding -- idiopathic thrombocytopenic purpura -- platelet -- primary immune thrombocytopenia -- romiplostim -- thrombopoietin receptor agonists; Hematology -- Periodicals; Blood -- Diseases -- Periodicals; Blood -- Periodicals; 616.15005
• DOI: 10.1111/ejh.13221
• Languages: English
• ISSNs: 0902-4441

Abstract

Abstract: Background: Romiplostim is a thrombopoietin‐mimetic peptibody for adult refractory chronic immune thrombocytopenia (ITP). We aimed to describe ITP patients receiving romiplostim, platelet counts and romiplostim usage in UK clinical practice. Methods: This was a retrospective cohort study of patients in the UKITP Registry who received romiplostim between October 2009 and January 2015, including data up to 6 months before romiplostim initiation through follow‐up. Results: Of 1440 patients in the UKITP Registry, 118 adults with primary ITP were eligible. Before romiplostim, 22% had splenectomy, 12% received platelet transfusion, 97% received ≥ 1 different ITP medication and 77% received ≥ 3. Most patients (73%) initiated romiplostim ≥ 1 year after ITP diagnosis (chronic phase). The mean duration of romiplostim treatment was 5.7 (SE 0.9) months, and the median was 1.4 months (IQR: 0.2, 6.5). Mean platelet count before romiplostim was 38 × 10 9 /L, rising to 103 × 10 9 /L within 1 month, and remaining 50‐150 × 10 9 /L through up to 3 years of follow‐up. After romiplostim, 4% of patients had splenectomy, 6% received platelet transfusion, and 57% received just one ITP medication other than romiplostim. Conclusion: The study provides valuable insights into the real‐world use of romiplostim in primary ITP in routine practice and highlighted the timing of romiplostim initiation at different ITP disease phases.